Kish J A, Al-Sarraf M
Am J Clin Oncol. 1984 Oct;7(5):535-7.
Aclacinomycin-A was evaluated in a phase II trial for advanced head and neck cancer. A weekly infusion of 65 mg/m2 was used. Eighteen patients were entered. Fifteen patients were evaluable for response and toxicity. One was evaluable for toxicity only and two died before completion of a full course of therapy. One patient without previous chemotherapy achieved a PR in a neck node for a short time. Six patients had stable disease with a median to progression of 6 weeks. Major toxicity encountered was bone marrow suppression. Aclacinomycin-A appears to have no activity in squamous cancer of the head and neck.
对阿克拉霉素 - A进行了一项针对晚期头颈癌的II期试验评估。采用每周65 mg/m²的输注方案。纳入了18例患者。15例患者可评估疗效和毒性。1例仅可评估毒性，2例在完成整个疗程之前死亡。1例未接受过化疗的患者颈部淋巴结短期内达到部分缓解。6例患者病情稳定，至疾病进展的中位时间为6周。主要的毒性反应为骨髓抑制。阿克拉霉素 - A对头颈部鳞状癌似乎无活性。
